Argent Capital Management LLC bought a new stake in Celgene Corporation (NASDAQ:CELG) during the first quarter, according to its most recent filing with the SEC. The institutional investor bought 358,874 shares of the biopharmaceutical company’s stock, valued at approximately $44,655,000. Celgene Corporation makes up about 1.7% of Argent Capital Management LLC’s holdings, making the stock its 24th largest position.

Several other institutional investors have also recently bought and sold shares of CELG. Artisan Partners Limited Partnership boosted its position in Celgene Corporation by 14.2% in the first quarter. Artisan Partners Limited Partnership now owns 306,319 shares of the biopharmaceutical company’s stock valued at $38,115,000 after buying an additional 38,191 shares in the last quarter. Westpac Banking Corp boosted its position in Celgene Corporation by 31.2% in the first quarter. Westpac Banking Corp now owns 75,864 shares of the biopharmaceutical company’s stock valued at $8,612,000 after buying an additional 18,029 shares in the last quarter. WFG Advisors LP boosted its position in Celgene Corporation by 34.5% in the first quarter. WFG Advisors LP now owns 2,036 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 522 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in Celgene Corporation by 1.3% in the first quarter. Cornerstone Capital Management Holdings LLC. now owns 185,306 shares of the biopharmaceutical company’s stock valued at $23,056,000 after buying an additional 2,397 shares in the last quarter. Finally, Neuberger Berman Group LLC boosted its position in Celgene Corporation by 4.0% in the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after buying an additional 71,729 shares in the last quarter. 78.41% of the stock is currently owned by hedge funds and other institutional investors.

Celgene Corporation (NASDAQ CELG) opened at 137.06 on Tuesday. The stock has a market capitalization of $107.23 billion, a price-to-earnings ratio of 42.45 and a beta of 1.89. The stock’s 50 day moving average is $132.00 and its 200-day moving average is $123.32. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $139.00.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. The firm had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company’s revenue for the quarter was up 18.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.44 earnings per share. Equities research analysts anticipate that Celgene Corporation will post $7.32 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/08/argent-capital-management-llc-takes-position-in-celgene-corporation-nasdaqcelg.html.

Several research firms have commented on CELG. Cann reissued a “buy” rating and set a $175.00 target price on shares of Celgene Corporation in a research report on Tuesday, August 1st. Jefferies Group LLC reissued a “buy” rating and set a $160.00 target price on shares of Celgene Corporation in a research report on Monday, July 31st. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $175.00 target price (up previously from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. Argus raised shares of Celgene Corporation from a “hold” rating to a “buy” rating and lifted their target price for the stock from $96.93 to $160.00 in a research report on Monday, July 31st. Finally, Barclays PLC reissued a “hold” rating and set a $135.00 target price on shares of Celgene Corporation in a research report on Friday, July 28th. One analyst has rated the stock with a sell rating, six have given a hold rating and twenty-three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $147.06.

In related news, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the transaction, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Robert J. Hugin sold 175,970 shares of the firm’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the transaction, the insider now directly owns 1,033,909 shares of the company’s stock, valued at $138,688,553.26. The disclosure for this sale can be found here. Over the last three months, insiders sold 235,255 shares of company stock valued at $31,377,042. Corporate insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.